INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $313 | -17.6% | 6,000 | 0.0% | 0.02% | -25.0% |
| Q2 2023 | $380 | +9.5% | 6,000 | -6.2% | 0.03% | -3.0% |
| Q1 2023 | $347 | +2.4% | 6,400 | 0.0% | 0.03% | -15.4% |
| Q4 2022 | $339 | -99.9% | 6,400 | 0.0% | 0.04% | +5.4% |
| Q3 2022 | $298,000 | -18.4% | 6,400 | 0.0% | 0.04% | -15.9% |
| Q2 2022 | $365,000 | -9.7% | 6,400 | -3.0% | 0.04% | +2.3% |
| Q1 2022 | $404,000 | +8.6% | 6,600 | -7.0% | 0.04% | +4.9% |
| Q4 2021 | $372,000 | +40.4% | 7,100 | 0.0% | 0.04% | +5.1% |
| Q3 2021 | $265,000 | -27.8% | 7,100 | -21.1% | 0.04% | -29.1% |
| Q2 2021 | $367,000 | +10.2% | 9,000 | -8.2% | 0.06% | +3.8% |
| Q1 2021 | $333,000 | -4.9% | 9,800 | -10.9% | 0.05% | 0.0% |
| Q4 2020 | $350,000 | +26.4% | 11,000 | +1.9% | 0.05% | +26.2% |
| Q3 2020 | $277,000 | +1.8% | 10,800 | +1.9% | 0.04% | +2.4% |
| Q2 2020 | $272,000 | – | 10,600 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |